Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in Brisbane, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Day One Biopharmaceuticals reports robust Q3 earnings and eyes growth opportunities

Day One Biopharmaceuticals delivered strong Q3 earnings, showcasing commercial success and financial stability, with OJEMDA leading revenue generation.
Challenges lie in maintaining patient starts and addressing physician feedback, while opportunities in trials and partnerships offer avenues for growth and innovation.
Overall, Day One Biopharmaceuticals' performance reflects a promising trajectory with a solid foundation for future expansion and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers, today announced the appointment of Jaa Roberson as chief people officer. In her role, Ms. Roberson will oversee all aspects of Day One's human resources and talent acquisition efforts.

Day One Appoints Jaa Roberson as Chief People Officer

SOUTH SAN FRANCISCO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced the appointment of Scott Garland to the Company's board of directors. Mr. Garland is a 30-year veteran of the biopharmaceutical industry with deep commercial and executive leadership experience.

Day One Appoints Scott Garland to Board of Directors

DAY101 Granted Rare Pediatric Disease Designation from FDA

Day One Reports Second Quarter 2021 Financial Results and Corporate Progress

Shares of Day One Biopharmaceuticals Inc. gained 9.4% in premarket trading on Monday after the company said its experimental glioma treatment received an orphan designation in Europe. The drug candidate has already received a Breakthrough Therapy designation from U.S. regulators for one indication and an orphan designation as a treatment for malignant glioma.

Day One Biopharma's experimental glioma drug gets an orphan designation in Europe

SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced that the European Commission has granted orphan designation for the Company's lead product candidate, DAY101, for the treatment of glioma. The designation was based on a positive opinion from the European Medicines Agency Committee for Orphan Medicinal Products.

Day One Receives Orphan Designation from the European Commission for DAY101 for the Treatment of Glioma

SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced the closing of its initial public offering of 11,500,000 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 1,500,000 additional shares of common stock, at a public offering price of $16.00 per share. All of the shares were offered by Day One. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Day One, were $184.0 million. The shares began trading on the Nasdaq Global Select Market on May 27, 2021 under the ticker symbol “DAWN.”

Day One Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Centessa Pharmaceuticals PLC

Dynamics Special Purpose Corp

FIGS

Flywire Corp

Fifth Wall Acquisition Corp III

Singular Genomics Systems

Paymentus Holdings

Uber

ZipRecruiter

Zoom Video

Six IPOs raised $1.8 billion ahead of the short holiday week, joined by one direct listing and five SPACs. Returns bounced back after tumultuous trading earlier this month, with the week's deals all finishing above issue.

U.S. IPO Weekly Recap And Week Ahead

SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced the pricing of its initial public offering of 10,000,000 shares of its common stock at a public offering price of $16.00 per share. All of the shares are being offered by Day One. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Day One, are expected to be $160.0 million. The shares are expected to begin trading on the Nasdaq Global Select Market on May 27, 2021 under the ticker symbol “DAWN.” The offering is expected to close on June 1, 2021, subject to the satisfaction of customary closing conditions. In addition, Day One has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Day One Announces Pricing of Upsized Initial Public Offering

Day One Biopharmaceuticals Inc. , which specializes in developing cancer treatments for children, upsized its initial public offering on Wednesday to 10 million shares from a previous plan to offer 8.4 million. The company is still proposing a price range of $14 to $16 a share.

Day One Biopharmaceuticals upsizes IPO to 10 million shares from 8.4 million

ZipRecruiter, the fourth company this year to go ahead with a direct listing, is leading a slate of seven companies to the public equity markets this week.

ZipRecruiter, Another Direct Listing, Is One of Seven IPOs This Week

News for Day One Biopharmaceuticals Stock (DAWN)